Cited by 657SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies

The DOI matches its Crossref record; 43 of the 43 references it cites were found in a registry or an index.

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Open access

Network for Genomic Surveillance in South Africa, Cele, Sandile, COMMIT-KZN Team, Gazy, Inbal, Jackson, Laurelle, Hwa, Shi-Hsia, Tegally, Houriiyah, Lustig, Gila, Giandhari, Jennifer, Pillay, Sureshnee, Wilkinson, Eduan, Naidoo, Yeshnee, Karim, Farina, Ganga, Yashica, Khan, Khadija, Bernstein, Mallory, Balazs, Alejandro B., Gosnell, Bernadett I., Hanekom, Willem, Moosa, Mahomed-Yunus S., Lessells, Richard J., de Oliveira, Tulio, Sigal, Alex·2021·Nature

DOI 10.1038/s41586-021-03471-wPMC PMC9867906

Published version of a preprint

Open this paper in CoChat — free account Open PDF

Abstract

SARS-CoV-2 variants of concern (VOC) have arisen independently at multiple locations 1,2 and may reduce the efficacy of current vaccines that target the spike glycoprotein of SARS-CoV-2 3. Here, using a live-virus neutralization assay, we compared the neutralization of a non-VOC variant with the 501Y.V2 VOC (also known as B.1.351) using plasma collected from adults who were hospitalized with COVID-19 during the two waves of infection in South Africa, the second wave of which was dominated by infections with the 501Y.V2 variant. Sequencing demonstrated that infections of plasma donors from the first wave were with viruses that did not contain the mutations associated with 501Y.V2, except for one infection that contained the E484K substitution in the receptor-binding domain. The 501Y.V2 virus variant was effectively neutralized by plasma from individuals who were infected during the second wave. The first-wave virus variant was effectively neutralized by plasma from first-wave infections. However, the 501Y.V2 variant was poorly cross-neutralized by plasma from individuals with first-wave infections; the efficacy was reduced by 15.1-fold relative to neutralization of 501Y.V2 by plasma from individuals infected in the second wave. By contrast, cross-neutralization of first-wave virus variants using plasma from individuals with second-wave infections was more effective, showing only a 2.3-fold decrease relative to neutralization of first-wave virus variants by plasma from individuals infected in the first wave. Although we tested only one plasma sample from an individual infected with a SARS-CoV-2 variant with only the E484K substitution, this plasma sample potently neutralized both variants. The observed effective neutralization of first-wave virus by plasma from individuals infected with 501Y.V2 provides preliminary evidence that vaccines based on VOC sequences could retain activity against other circulating SARS-CoV-2 lineages.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1038/s41586-021-03471-w

Cites

43 of 43 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615
Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2020) · doi:10.1101/2020.12.21.20248640 · Cited by 2,535
Self-citation
Detection of a SARS-CoV-2 variant of concern in South Africa
Tegally, H., Wilkinson, E., Giovanetti, M., Iranzadeh, A., Fonseca, V., Giandhari, J., Doolabh, D., Pillay, S., San, E. J., Msomi, N., et al. (2021) · Nature · doi:10.1038/s41586-021-03402-9 · Cited by 2,510
Self-citation
Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7
Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature · doi:10.1038/s41586-021-03398-2 · Cited by 2,312
Convergent Antibody Responses to SARS-CoV-2 in Convalescent Individuals
Robbiani, D. F., Gaebler, C., Muecksch, F., Lorenzi, J. C. C., Wang, Z., Cho, A., Agudelo, M., Barnes, C. O., Gazumyan, A., Finkin, S., et al. (2020) · Nature · doi:10.1038/s41586-020-2456-9 · Cited by 1,853
Self-citation
Evolution of antibody immunity to SARS-CoV-2
Gaebler, C., Wang, Z., Lorenzi, J. C. C., Muecksch, F., Finkin, S., Tokuyama, M., Cho, A., Jankovic, M., Schaefer-Babajew, D., Oliveira, T. Y., et al. (2021) · Nature · doi:10.1038/s41586-021-03207-w · Cited by 1,674
Self-citation
SARS-CoV-2 neutralizing antibody structures inform therapeutic strategies
Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K.-M. A., Esswein, S. R., Gristick, H. B., Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., et al. (2020) · Nature · doi:10.1038/s41586-020-2852-1 · Cited by 1,599
Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil
Faria, N. R., Mellan, T. A., Whittaker, C., Claro, I. M., Candido, D. D. S., Mishra, S., Crispim, M. A. E., Sales, F. C. S., Hawryluk, I., McCrone, J. T., et al. (2021) · Science · doi:10.1126/science.abh2644 · Cited by 1,461
Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology
Piccoli, L., Park, Y.-J., Tortorici, M. A., Czudnochowski, N., Walls, A. C., Beltramello, M., Silacci-Fregni, C., Pinto, D., Rosen, L. E., Bowen, J. E., et al. (2020) · Cell · doi:10.1016/j.cell.2020.09.037 · Cited by 1,395
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
Garcia-Beltran, W. F., Lam, E. C., St. Denis, K., Nitido, A. D., Garcia, Z. H., Hauser, B. M., Feldman, J., Pavlovic, M. N., Gregory, D. J., Poznansky, M. C., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.013 · Cited by 1,353
Self-citation

Show all 31 references

Sorted by citations

Items 301–400 of 657

Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection
Glöckner, S., Hornung, F., Baier, M., Weis, S., Pletz, M. W., Deinhardt‐Emmer, S., Löffler, B., & the CoNAN Study Group (2021) · Viruses · doi:10.3390/v13102003 · Cited by 19
Human-to-dog transmission of SARS-CoV-2, Colombia
Rivero, R., Garay, E., Botero, Y., Coll, H. A. S., Gastelbondo, B., Muñoz, M., Ballesteros, N., Castañeda, S., Patiño, L. H., Ramírez, J. D., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-11847-9 · Cited by 20
Immunogenicity of adjuvanted plant-produced SARS-CoV-2 Beta spike VLP vaccine in New Zealand white rabbits
O’Kennedy, M. M., Abolnik, C., Smith, T., Motlou, T. P., Goosen, K., Sepotokele, K. M., Roth, R., du Preez, I., Truyts, A., Stark, H. C., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.050 · Cited by 20
Vaccination of SARS-CoV-2-infected individuals expands a broad range of clonally diverse affinity-matured B cell lineages
Chernyshev, M., Sakharkar, M., Connor, R. I., Dugan, H. L., Sheward, D. J., Rappazzo, C. G., Stålmarck, A., Forsell, M. N. E., Wright, P. F., Corcoran, M., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-37972-1 · Cited by 17
Natural variants in SARS-CoV-2 Spike protein pinpoint structural and functional hotspots with implications for prophylaxis and therapeutic strategies
Pokhrel, S., Kraemer, B. R., Burkholz, S., & Mochly‐Rosen, D. (2021) · Scientific Reports · doi:10.1038/s41598-021-92641-x · Cited by 20
Hospital mortality in COVID-19 patients in Belgium treated with statins, ACE inhibitors and/or ARBs
Byttebier, G., Belmans, L., Alexander, M., Saxberg, B. E. H., Spiegeleer, B. M. J. D., Spiegeleer, A. D., Devreker, N., Praet, J. T. V., Vanhove, K., Reybrouck, R., et al. (2021) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2021.1920271 · Cited by 19
Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore
Wang, B., Goh, Y. S., Prince, T., Ngoh, E. Z. X., Salleh, S. N. M., Hor, P. X., Loh, C. Y., Fong, S., Hartley, C. S., Tan, S. Y., et al. (2021) · npj Vaccines · doi:10.1038/s41541-021-00389-2 · Cited by 19
Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern
Lien, C.-E., Kuo, T., Lin, Y., Lian, W., Lin, M., Liu, L. T.-C., Cheng, J., Chou, Y., & Chen, C. (2021) · Clinical Infectious Diseases · doi:10.1093/cid/ciab711 · Cited by 16
Evaluating Antibody Mediated Protection against Alpha, Beta, and Delta SARS-CoV-2 Variants of Concern in K18-hACE2 Transgenic Mice
Wong, T. Y., Horspool, A. M., Russ, B. P., Ye, C., Lee, K. S., Winters, M. T., Bevere, J. R., Miller, O. A., Rader, N. A., Cooper, M., et al. (2022) · Journal of Virology · doi:10.1128/jvi.02184-21 · Cited by 17
Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection
Clark, N. M., Janaka, S. K., Hartman, W. R., Stramer, S. L., Goodhue, E., Weiss, J., Evans, D. T., & Connor, J. P. (2022) · PLoS ONE · doi:10.1371/journal.pone.0257930 · Cited by 23
Convergent Evolution of Multiple Mutations Improves the Viral Fitness of SARS-CoV-2 Variants by Balancing Positive and Negative Selection
Upadhyay, V., Patrick, C., Lucas, A., & Mallela, K. M. G. (2022) · Biochemistry · doi:10.1021/acs.biochem.2c00132 · Cited by 17
Baseline Sequencing Surveillance of Public Clinical Testing, Hospitals, and Community Wastewater Reveals Rapid Emergence of SARS-CoV-2 Omicron Variant of Concern in Arizona, USA
Smith, M. F., Holland, S. C., Lee, M. B., Hu, J. C., Pham, N. C., Sullins, R. A., Holland, L. A., Mu, T., Thomas, A. W., Fitch, R., et al. (2023) · mBio · doi:10.1128/mbio.03101-22 · Cited by 17
Biophysical principles predict fitness of SARS-CoV-2 variants
Wang, D., Huot, M., Mohanty, V., & Shakhnovich, E. I. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2314518121 · Cited by 19
An update on host immunity correlates and prospects of re-infection in COVID-19
Negi, N., Maurya, S. P., Singh, R., & Das, B. K. (2021) · International Reviews of Immunology · doi:10.1080/08830185.2021.2019727 · Cited by 20
Complete Protection of Nasal and Lung Airways Against SARS-CoV-2 Challenge by Antibody Plus Th1 Dominant N- and S-Specific T-Cell Responses to Subcutaneous Prime and Thermally-Stable Oral Boost Bivalent hAd5 Vaccination in an NHP StudyPreprint
Gabitzsch, E., Safrit, J. T., Verma, M., Rice, A., Sieling, P. A., Zakin, L., Shin, A., Morimoto, B., Adisetiyo, H., Wong, R. M. H., et al. (2020) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2020.12.08.416297 · Cited by 17
Structural and computational insights into the SARS-CoV-2 Omicron RBD-ACE2 interactionPreprint
Lan, J., He, X., Ren, Y., Wang, Z., Zhou, H., Fan, S., Zhu, C., Liu, D., Shao, B., Liu, T., et al. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.03.474855 · Cited by 16
Effect of time and titer in convalescent plasma therapy for COVID-19
de Candia, P., Prattichizzo, F., Garavelli, S., Grotta, R. L., Rosa, A. D., Pontarelli, A., Parrella, R., Ceriello, A., & Matarese, G. (2021) · iScience · doi:10.1016/j.isci.2021.102898 · Cited by 16
Advancements in Testing Strategies for COVID-19
Asghar, R., Rasheed, M., Hassan, J. U., Rafique, M., Khan, M., & Deng, Y. (2022) · Biosensors · doi:10.3390/bios12060410 · Cited by 17
Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status
Fonseca, P. L. C., Moreira, F. R. R., de Souza, R. M., Guimarães, N. R., Carvalho, N. D. O., Adelino, T., Alves, H. J., Alvim, L. B., Cândido, D. D. S., Coelho, H. P., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac064 · Cited by 16
Novel GO/LiCr2O4 nanocomposite synthesis, characterizations and electrode testing for electrochemical applications
Yaqoob, T., Rani, M., Neffati, R., Janjua, N. K., Khan, S., Arshad, M., & Murtaza, G. (2022) · Materials Science and Engineering B · doi:10.1016/j.mseb.2022.116118 · Cited by 17
Modelling optimal lockdowns with waning immunity
Goenka, A., Liu, L., & Nguyen, M. (2022) · Economic Theory · doi:10.1007/s00199-022-01468-8 · Cited by 18
Clonal diversity predicts persistence of SARS-CoV-2 epitope-specific T-cell response
Zornikova, K. V., Khmelevskaya, A. A., Sheetikov, S. A., Kiryukhin, D. O., Shcherbakova, O. V., Titov, A., Zvyagin, I. V., & Efimov, G. A. (2022) · Communications Biology · doi:10.1038/s42003-022-04250-7 · Cited by 17
Antibody-dependent cellular cytotoxicity against SARS-CoV-2 Omicron sub-lineages is reduced in convalescent sera regardless of infecting variant
Richardson, S. I., Kgagudi, P., Manamela, N. P., Kaldine, H., Venter, E. M., Pillay, T., Lambson, B. E., van der Mescht, M. A., Hermanus, T., Balla, S. R., et al. (2022) · Cell Reports Medicine · doi:10.1016/j.xcrm.2022.100910 · Cited by 18
Safety and immunogenicity of booster vaccination and fractional dosing with Ad26.COV2.S or BNT162b2 in Ad26.COV2.S-vaccinated participants
Riou, C., Bhiman, J. N., Ganga, Y., Sawry, S., Ayres, F., Baguma, R., Balla, S. R., Benede, N., Bernstein, M. P., Besethi, A. S., et al. (2024) · PLOS Global Public Health · doi:10.1371/journal.pgph.0002703 · Cited by 16
Self-citation
Are convalescent plasma stocks collected during former COVID‐19 waves still effective against current SARS‐CoV ‐2 variants?
Focosi, D., Franchini, M., Joyner, M. J., & Casadevall, A. (2022) · Vox Sanguinis · doi:10.1111/vox.13239 · Cited by 15
Monitoring the propagation of SARS CoV2 variants by tracking identified mutation in wastewater using specific RT-qPCRPreprint
Wurtzer, S., Waldman, P., Levert, M., Mouchel, J., Gorgé, O., Boni, M., Maday, Y., Maréchal, V., & Moulin, L. (2021) · medRxiv · doi:10.1101/2021.03.10.21253291 · Cited by 16
Broad neutralization against SARS-CoV-2 variants induced by a modified B.1.351 protein-based COVID-19 vaccine candidatePreprint
Su, D., Li, X., He, C., Huang, X., Chen, M., Wang, Q., Qin, W., Liang, Y. S., Xu, R., Wu, J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.16.444369 · Cited by 15
S:D614G and S:H655Y are Gateway Mutations that Act Epistatically to Promote SARS-CoV-2 Variant FitnessPreprint
Yurkovetskiy, L., Egri, S. B., Kurhade, C., Díaz-Salinas, M. A., Jaimes, J. A., Nyalile, T., Xie, X., Choudhary, M. C., Dauphin, A., Li, J. Z., et al. (2023) · SSRN Electronic Journal · doi:10.1101/2023.03.30.535005 · Cited by 18
Outbreaks of publications about emerging infectious diseases: the case of SARS-CoV-2 and Zika virus
Ipekci, A. M., Buitrago‐García, D., Meili, K. W., Krauer, F., Prajapati, N., Thapa, S., Wildisen, L., Araujo-Chaveron, L., Baumann, L., Shah, S., et al. (2021) · BMC Medical Research Methodology · doi:10.1186/s12874-021-01244-7 · Cited by 16
Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting
Lownik, J. C., Farrar, J. S., Way, G. W., McKay, A., Roychoudhury, P., Greninger, A. L., & Martin, R. (2021) · Diagnostics · doi:10.3390/diagnostics11101788 · Cited by 16
Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
Wines, B. D., Kurtovic, L., Trist, H. M., Esparon, S. E., López, E., Chappin, K., Chan, L., Mordant, F. L., Lee, W. S., Gherardin, N. A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.889372 · Cited by 15
SARS-COV-2/COVID-19: scenario, epidemiology, adaptive mutations, and environmental factors
Asghar, A., Imran, H. M., Bano, N., Maalik, S., Mushtaq, S., Hussain, A., Varjani, S., Aleya, L., Iqbal, H. M. N., & Bilal, M. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-22333-0 · Cited by 16
SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19
Liang, H., Wu, Y., Yau, V., Yin, H.-X., Lowe, S., Bentley, R., Ahmed, M. A., Zhao, W., & Sun, C. (2022) · Vaccines · doi:10.3390/vaccines10091538 · Cited by 16
Could the New BA.2.75 Sub-Variant Cause the Emergence of a Global Epidemic of COVID-19? A Scoping Review
Shaheen, N., Mohamed, A., Attalla, A., Diab, R. A., Swed, S., Nashwan, A. J., Rababah, A. A., Hefnawy, M. T., Soliman, Y. Y., Abdelwahab, O. A., et al. (2022) · Infection and Drug Resistance · doi:10.2147/idr.s387551 · Cited by 16
Structural remodeling of SARS-CoV-2 spike protein glycans reveals the regulatory roles in receptor-binding affinity
Hsu, Y., Frank, M., Mukherjee, D., Shchurik, V., Makarov, A. A., & Mann, B. F. (2022) · Glycobiology · doi:10.1093/glycob/cwac077 · Cited by 17
A potent, broadly protective vaccine against SARS-CoV-2 variants of concern
Wang, Z., An, J., Liu, K., Yü, P., Fang, X. D., Li, J., Zhu, H., Zhu, Q., Huang, C., Zhang, C., et al. (2022) · npj Vaccines · doi:10.1038/s41541-022-00571-0 · Cited by 15
Ongoing evolution of SARS-CoV-2 drives escape from mRNA vaccine-induced humoral immunity
Roederer, A. L., Cao, Y., Denis, K. S., Sheehan, M. L., Li, C. J., Lam, E. C., Gregory, D. J., Poznansky, M. C., Iafrate, A. J., Canaday, D. H., et al. (2024) · Cell Reports Medicine · doi:10.1016/j.xcrm.2024.101850 · Cited by 18
Self-citation
Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations
Hendy, M. A., Kaufman, S., & Ponga, M. R. (2021) · Scientific Reports · doi:10.1038/s41598-021-01081-0 · Cited by 17
Investigating Constraints Along the Plant Secretory Pathway to Improve Production of a SARS-CoV-2 Spike Vaccine Candidate
Margolin, E., Verbeek, M., de Moor, W. R. J., Chapman, R., Meyers, A., Schäfer, G., Williamson, A., & Rybicki, E. (2022) · Frontiers in Plant Science · doi:10.3389/fpls.2021.798822 · Cited by 15
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)–Specific Memory B Cells From Individuals With Diverse Disease Severities Recognize SARS-CoV-2 Variants of Concern
Lyski, Z. L., Brunton, A. E., Strnad, M., Sullivan, P. E., Siegel, S. A. R., Tafesse, F., Slifka, M. K., & Messer, W. B. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab585 · Cited by 16
COVID-19 Vaccination and Public Health Countermeasures on Variants of Concern in Canada: Evidence From a Spatial Hierarchical Cluster Analysis
Adeyinka, D. A., Neudorf, C. O., Camillo, C. A., Marks, W. N., & Muhajarine, N. (2022) · JMIR Public Health and Surveillance · doi:10.2196/31968 · Cited by 16
The Landscape of Neutralizing Monoclonal Antibodies (nAbs) for Treatment and Prevention of COVID-19
Almeida-Oliveira, A., Freire, D. P. B., de Andrade, A. R., Marques, A. D. M., Madeira, L. D. S., Senna, J. P. M., da Silveira, I. A. F. B., & Fialho, B. D. C. (2023) · Journal of Pharmaceutical Innovation · doi:10.1007/s12247-023-09713-w · Cited by 17
Neutralizing Antibody Responses After SARS-CoV-2 Infection in End-Stage Kidney Disease and Protection Against Reinfection
Muir, L., Jaffer, A., Rees-Spear, C., Gopalan, V., Chang, F. Y., Fernando, R., Vaitkute, G., Roustan, C., Rosa, A., Earl, C. P., et al. (2021) · Kidney International Reports · doi:10.1016/j.ekir.2021.03.902 · Cited by 15
Cellular senescence as a source of SARS‐CoV‐2 quasispecies
Karakasiliοtis, I., Lаgopati, N., Evangelou, K., & Gorgoulis, V. G. (2021) · FEBS Journal · doi:10.1111/febs.16230 · Cited by 15
SARS-CoV-2 Variants: Mutations and Effective Changes
Park, G., & Hwang, B. H. (2021) · Biotechnology and Bioprocess Engineering · doi:10.1007/s12257-021-0327-3 · Cited by 17
In-solution buffer-free digestion allows full-sequence coverage and complete characterization of post-translational modifications of the receptor-binding domain of SARS-CoV-2 in a single ESI–MS spectrum
Espinosa, L. A., Ramos, Y., Andújar, I., Alegre, E. O. T., Cabrera, G., Martin, A. M., Roche, D., Chinea, G., Béquet‐Romero, M., González, I., et al. (2021) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-021-03721-w · Cited by 15
The Role of Serology Testing in the Context of Immunization Policies for COVID-19 in Latin American Countries
Ferreira, C. D. S., Dantés, H. G., Bellei, N., López, E. L., Crespo, K. A. N., O’Ryan, M., & Villegas, J. (2021) · Viruses · doi:10.3390/v13122391 · Cited by 16
The spike glycoprotein of highly pathogenic human coronaviruses: structural insights for understanding infection, evolution and inhibition
Qiao, S., Zhang, S., Ge, J., & Wang, X. (2022) · FEBS Open Bio · doi:10.1002/2211-5463.13454 · Cited by 16
Differences between Omicron SARS-CoV-2 RBD and other variants in their ability to interact with cell receptors and monoclonal antibodies
Giron, C. C., Laaksonen, A., & da Silva, F. L. B. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2095305 · Cited by 18
Cellular and humoral immune responses to SARS-CoV-2 vaccination in patients after CD19.CAR T-cell therapy
Reimann, H., Kremer, A. N., Blumenberg, V., Schmidt, K. G., Aigner, M., Jacobs, B., Eisenhauer, N., Kämpf, A., Rösler, W., Kharboutli, S., et al. (2022) · Blood Advances · doi:10.1182/bloodadvances.2022007806 · Cited by 15
Genomic epidemiology of SARS-CoV-2 in Mauritius reveals a new wave of infections dominated by the B.1.1.318, a variant under investigationPreprint
Tegally, H., Ramuth, M., Amoaka, D., Scheepers, C., Wilkinson, E., Giovanetti, M., Lessells, R. J., Giandhari, J., Ismail, A., Martin, D. P., et al. (2021) · medRxiv · doi:10.1101/2021.06.16.21259017 · Cited by 13
Self-citation
Rapid and Flexible RT-qPCR Surveillance Platforms To Detect SARS-CoV-2 Mutations
Spieß, K., Gunalan, V., Marving, E. L., Nielsen, S. H., Jørgensen, M. G. P., Fomsgaard, A. S., Nielsen, L., Alfaro‐Núñez, A., Karst, S. M., Mortensen, S., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03591-22 · Cited by 24
The Immunopathobiology of SARS-CoV-2 Infection
Patel, M., Shahjin, F., Cohen, J. D., Hasan, M., Machhi, J., Chugh, H., Singh, S., Das, S., Kulkarni, T. A., Herskovitz, J., et al. (2021) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuab035 · Cited by 15
SARS‐CoV‐2 R.1 lineage variants that prevailed in Tokyo in March 2021
Nagano, K., Sassa, C. T., Iwasaki, Y., Takatsuki, Y., Yuasa, S., Takahashi, Y., Nakajima, J., Sonobe, K., Ichimura, N., Nukui, Y., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27240 · Cited by 14
Sensitivity of SARS-CoV-2 Variants to Neutralization by Convalescent Sera and a VH3-30 Monoclonal Antibody
Yue, S., Li, Z., Lin, Y., Yang, Y., Yuan, M., Pan, Z., Li, H., Gao, L., Zhou, J., Tang, J., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.751584 · Cited by 13
Insect protease inhibitors; promising inhibitory compounds against SARS-CoV-2 main protease
Hemmati, S. A., & Tabein, S. (2022) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2022.105228 · Cited by 14
Evolutionary dynamics of the severe acute respiratory syndrome coronavirus 2 genomes
Qian, Z., Li, P., Tang, X., & Lü, J. (2022) · Medical Review · doi:10.1515/mr-2021-0035 · Cited by 14
The End or a New Era of Development of SARS-CoV-2 Virus: Genetic Variants Responsible for Severe COVID-19 and Clinical Efficacy of the Most Commonly Used Vaccines in Clinical Practice
Miteva, D., Kitanova, M., Batselova, H., Lazova, S., Chervenkov, L., Peshevska-Sekulovska, M., Sekulovski, M., Gulinac, M., Vasilev, G., Tomov, L., et al. (2023) · Vaccines · doi:10.3390/vaccines11071181 · Cited by 16
Specific Detection of SARS-CoV-2 Variants B.1.1.7 (Alpha) and B.1.617.2 (Delta) Using a One-Step Quantitative PCR Assay
Erster, O., Mendelson, E., Kabat, A., Levy, V., Mannasse, B., Asraf, H., Azar, R., Ali, Y., Bucris, E. D., Bar-Ilan, D., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.02176-21 · Cited by 14
SARS-CoV-2 vaccination induces neutralizing antibodies against pandemic and pre-emergent SARS-related coronaviruses in monkeysPreprint
Saunders, K. O., Lee, E., Parks, R., Martinez, D. R., Li, D., Chen, H., Edwards, R. J., Gobeil, S., Barr, M., Mansouri, K., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.02.17.431492 · Cited by 14
SARS-CoV-2 cell-to-cell spread occurs rapidly and is insensitive to antibody neutralizationPreprint
Jackson, L., Rodel, H. E., Hwa, S.-H., Cele, S., Ganga, Y., Tegally, H., Bernstein, M. P., Giandhari, J., COMMIT-KZN Team, Gosnell, B. I., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.06.01.446516 · Cited by 16
Self-citation
BNT162b2 vaccine effectiveness was marginally affected by the SARS-CoV-2 beta variant in fully vaccinated individuals
Mor, O., Zuckerman, N. S., Hazan, I., Fluss, R., Ash, N., Ginish, N., Mendelson, E., Alroy-Preis, S., Freedman, L., & Huppert, A. (2022) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2021.10.011 · Cited by 13
Structural and functional insights into the major mutations of SARS-CoV-2 Spike RBD and its interaction with human ACE2 receptor
Gurung, A. B., Ali, M. A., Lee, J., Farah, M. A., Al‐Anazi, K. M., Al-Hemaid, F. M. A., & Sami, H. (2021) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2021.101773 · Cited by 13
Computational design of medicinal compounds to inhibit RBD-hACE2 interaction in the Omicron variant: unveiling a vulnerable target site
Shahab, M., Akter, S., Sarkar, M. M. H., Banu, T. A., Goswami, B., Chowdhury, S. F., Naser, S. R., Habib, M. A., Shaikh, A. A., Saki, M., et al. (2023) · Informatics in Medicine Unlocked · doi:10.1016/j.imu.2023.101281 · Cited by 13
Survey of SARS-CoV-2 genetic diversity in two major Brazilian cities using a fast and affordable Sanger sequencing strategy
Dorlass, E. G., Lourenço, K. L., Magalhães, R. D. M., Sato, H. I., Fiorini, A., Peixoto, R. B., Coelho, H. P., Telezynski, B. L., Scagion, G. P., Ometto, T., et al. (2021) · Genomics · doi:10.1016/j.ygeno.2021.10.015 · Cited by 13
Maturation of SARS-CoV-2 Spike-specific memory B cells drives resilience to viral escape
Marzi, R., Bassi, J., Silacci-Fregni, C., Bartha, I., Muoio, F., Culap, K., Sprugasci, N., Lombardo, G., Saliba, C., Cameroni, E., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105726 · Cited by 12
COVID-19: A state of art on immunological responses, mutations, and treatment modalities in riposte
Gong, X., Khan, A., Wani, M. Y., Ahmad, A., & Duse, A. G. (2022) · Journal of Infection and Public Health · doi:10.1016/j.jiph.2022.12.019 · Cited by 15
Haplotype distribution of SARS-CoV-2 variants in low and high vaccination rate countries during ongoing global COVID-19 pandemic in early 2021
Bui, N.-N., Lin, Y.-T., Huang, S.-H., & Lin, C. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105164 · Cited by 13
Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines
Pecetta, S., Kratochvil, S., Kato, Y., Vadivelu, K., & Rappuoli, R. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.120.000285 · Cited by 11
A mRNA Vaccine Encoding for a RBD 60-mer Nanoparticle Elicits Neutralizing Antibodies and Protective Immunity Against the SARS-CoV-2 Delta Variant in Transgenic K18-hACE2 Mice
Brandys, P., Montagutelli, X., Merenkova, I., Barut, G. T., Thiel, V., Schork, N. J., Trüeb, B. S., Conquet, L., Deng, A., Antanasijevic, A., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.912898 · Cited by 11
mRNA Vaccines Against COVID-19 as Trailblazers for Other Human Infectious Diseases
Brandi, R., Paganelli, A., D’Amelio, R., Giuliani, P., Lista, F. R., Salemi, S., & Paganelli, R. (2024) · Vaccines · doi:10.3390/vaccines12121418 · Cited by 13
Temporal Dominance of B.1.1.7 over B.1.354 SARS-CoV-2 Variant: A Hypothesis Based on Areas of Variant Co-Circulation
Kostaki, E. G., Tseti, I. K., Tsiodras, S., Pavlakis, G. N., Sfikakis, P. P., & Paraskevis, D. N. (2021) · Life · doi:10.3390/life11050375 · Cited by 13
Geopolitical issues in health and biosecurity concerning gain-of-function research, emergence and re-emergence of infectious diseases
Chrysanthus, C. S. (2022) · International Journal of Clinical Virology · doi:10.29328/journal.ijcv.1001043 · Cited by 12
The COVID-19 Humoral Immunological Status Induced by CoronaVac and AstraZeneca Vaccines Significantly Benefits from a Booster Shot with the Pfizer Vaccine
Farias, J. P., da Silva, P. D. S., Fogaça, M. M. C., Santana, I. V. R., Luiz, W. B., Birbrair, A., & Amorim, J. H. (2022) · Journal of Virology · doi:10.1128/jvi.00177-22 · Cited by 12
Vaccination with Omicron Inactivated Vaccine in Pre-vaccinated Mice Protects against SARS-CoV-2 Prototype and Omicron Variants
Zhang, Y., Tan, W., Lou, Z., Zhao, Y., Zhang, J., Liang, H., Li, N., Zhu, X., Ding, L., Huang, B., et al. (2022) · Vaccines · doi:10.3390/vaccines10071149 · Cited by 11
Association Between Human Immunodeficiency Virus Viremia and Compromised Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Beta Variant
Hwa, S.-H., Snyman, J., Bernstein, M. P., Ganga, Y., Cele, S., Muema, D., Tan, C. W., Khan, K., Karim, F., Hanekom, W. A., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac343 · Cited by 12
Self-citation
SARS-CoV-2 variants of concern: a review
Sarkar, M. S., & Madabhavi, I. (2022) · Monaldi Archives for Chest Disease · doi:10.4081/monaldi.2022.2337 · Cited by 14
Ad26.COV2.S priming provided a solid immunological base for mRNA-based COVID-19 booster vaccination
Geers, D., Sablerolles, R. S. G., van Baarle, D., Kootstra, N. A., Rietdijk, W. J. R., Schmitz, K. S., Gommers, L., Bogers, S., Nieuwkoop, N. J., van Dijk, L. L. A., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105753 · Cited by 12
The Impact of SARS-CoV-2 Lineages (Variants) and COVID-19 Vaccination on the COVID-19 Epidemic in South Africa: Regression Study
Mabuka, T., Naidoo, N., Ncube, N., Yiga, T., Ross, M. D., Kurehwa, K., Nyathi, M. N., Silaji, A., Ndemera, T., Lemeke, T., et al. (2023) · JMIRx Med · doi:10.2196/34598 · Cited by 12
SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise
Duerr, R., Crosse, K. M., Valero-Jimenez, A. M., & Dittmann, M. (2021) · Microorganisms · doi:10.3390/microorganisms9071389 · Cited by 12
Modelling how face masks and symptoms-based quarantine synergistically and cost-effectively reduce SARS-CoV-2 transmission in Bangladesh
Ferguson, E. A., Brum, E., Chowdhury, A., Chowdhury, S., Kundegorski, M. E., Mahmud, A. S., Purno, N. H., Sania, A., Steenson, R., Tasneem, M., et al. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100592 · Cited by 14
Neuroinvasion and neurotropism by SARS-CoV-2 variants in the K18-hACE2 mousePreprint
Seehusen, F., Clark, J. J., Sharma, P., Bentley, E. G., Kirby, A., Subramaniam, K. S., Wunderlin, S., Hughes, G. L., Patterson, E. I., Michael, B. D., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.04.16.440173 · Cited by 12
Rapid surveillance platforms for key SARS-CoV-2 mutations in DenmarkPreprint
Spieß, K., Gunalan, V., Marving, E. L., Nielsen, S. H., Jørgensen, M. G. P., Fomsgaard, A. S., Nielsen, L., Alfaro‐Núñez, A., Karst, S. M., Mortensen, S., et al. (2021) · medRxiv · doi:10.1101/2021.10.25.21265484 · Cited by 12
Antibody and T-Cell Responses 6 Months after Covid-19 mRNA-1273 Vaccination in Patients with Chronic Kidney Disease, on Dialysis, or Living with a Kidney TransplantPreprint
Sanders, J., Messchendorp, A. L., de Vries, R. D., Baan, C. C., van Baarle, D., van Binnendijk, R. S., Diavatopoulos, D. A., Geers, D., Schmitz, K. S., GeurtsvanKessel, C. H., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4070419 · Cited by 12
Multiviral Quartet Nanocages Elicit Broad Anti-Coronavirus Responses for Proactive VaccinologyPreprint
Hills, R. A., Tan, T. K., Cohen, A. A., Keeffe, J. R., Keeble, A. H., Gnanapragasam, P. N. P., Storm, K. N., Hill, M. L., Liu, S., Gilbert‐Jaramillo, J., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.02.24.529520 · Cited by 12
Evolution and viral properties of the SARS-CoV-2 BA.3.2 subvariant
Jule, Z., Roemer, C., Hossen, T., Sviridchik, V., Reedoy, K., Ganga, Y., Silangwe, S., Jackson, L., Norman, A., Karim, F., et al. (2026) · Virus Evolution · doi:10.1093/ve/veag011 · Cited by 10
Self-citation
Deep dissection of the antiviral immune profile of patients with COVID-19
Atanackovic, D., Avila, S. V., Lutfi, F. U., de Miguel‐Pérez, D., Fan, X., Sanchez‐Petitto, G., Mause, E. R. V., Siglin, J., Baddley, J. W., Mannuel, H. D., et al. (2021) · Communications Biology · doi:10.1038/s42003-021-02852-1 · Cited by 10
Mutation profile of SARS-CoV-2 genome in a sample from the first year of the pandemic in Colombia
Gálvez, J. M., Chaparro-Solano, H. M., Pinzón-Rondón, Á. M., Albornóz, L. L., Oviedo, J. M. P., Zapata-Gómez, F. A., Patiño-Aldana, A. F., Hernandez-Rodríguez, A. D., Quiroz, M. A. D., & Ruiz-Sternberg, Á. M. (2021) · Infection Genetics and Evolution · doi:10.1016/j.meegid.2021.105192 · Cited by 11
Emergence of novel combinations of SARS-CoV-2 spike receptor binding domain variants in Senegal
Ahouidi, A. D., Rodgers, M. A., Padane, A., Lèye, N., Olivo, A., Mbow, M., Mboup, A., Diaw, P. A., Dia, A., Harris, B., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-02874-z · Cited by 11
Complexity of Viral Epitope Surfaces as Evasive Targets for Vaccines and Therapeutic Antibodies
Miller, N. L., Raman, R., Clark, T., & Sasisekharan, R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.904609 · Cited by 12
A simple model to estimate the transmissibility of the Beta, Delta, and Omicron variants of SARS-COV-2 in South Africa
Yu, Y., Liu, Y., Zhao, S., & He, D. (2022) · Mathematical Biosciences & Engineering · doi:10.3934/mbe.2022485 · Cited by 11
SARS-CoV-2 intra-host single-nucleotide variants associated with disease severity
Zhang, Y., Jiang, N., Qi, W., Li, T., Zhang, Y., Wu, J., Zhang, H., Zhou, M., Cui, P., Yu, T., et al. (2022) · Virus Evolution · doi:10.1093/ve/veac106 · Cited by 11
Architecture of the SARS-CoV-2-specific T cell repertoire
Zornikova, K. V., Sheetikov, S. A., Rusinov, A. Y., Iskhakov, R. N., & Васильевна, Б. А. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1070077 · Cited by 10
The Stereotypic Response of the Pulmonary Vasculature to Respiratory Viral Infections: Findings in Mouse Models of SARS-CoV-2, Influenza A and Gammaherpesvirus Infections
Neck, S. D., Penrice-Randal, R., Clark, J. J., Sharma, P., Bentley, E. G., Kirby, A., Mega, D. F., Han, X., Owen, A., Hiscox, J. A., et al. (2023) · Viruses · doi:10.3390/v15081637 · Cited by 11
Characterization of intrinsic and effective fitness changes caused by temporarily fixed mutations in the SARS-CoV-2 spike E484 epitope and identification of an epistatic precondition for the evolution of E484A in variant Omicron
Schröder, S., Richter, A. M., Veith, T., Emanuel, J., Gudermann, L., Friedmann, K., Jeworowski, L. M., Mühlemann, B., Jones, T. C., Müller, M. A., et al. (2023) · Virology Journal · doi:10.1186/s12985-023-02154-4 · Cited by 10
SARS-CoV-2 infection in immunosuppression evolves sub-lineages which independently accumulate neutralization escape mutations
Lustig, G., Ganga, Y., Rodel, H. E., Tegally, H., Khairallah, A., Jackson, L., Cele, S., Khan, K., Jule, Z., Reedoy, K., et al. (2023) · Virus Evolution · doi:10.1093/ve/vead075 · Cited by 12
Self-citation
Potent Anti‐SARS‐CoV‐2 Efficacy of COVID‐19 Hyperimmune Globulin from Vaccine‐Immunized Plasma
Yu, D., Li, Y., Hong, L., Wu, J., Hu, Y., Peng, Y., Li, T., Hou, J., Huang, W., Guan, L., et al. (2022) · Advanced Science · doi:10.1002/advs.202104333 · Cited by 11
The changing health impact of vaccines in the COVID-19 pandemic: A modeling study
Cohen, J. A., Stuart, R. M., Panovska‐Griffiths, J., Mudimu, E., Abeysuriya, R., Kerr, C. C., Famulare, M., & Klein, D. J. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112308 · Cited by 14
Evaluation of mRNA-1273 against SARS-CoV-2 B.1.351 Infection in Nonhuman PrimatesPreprint
Corbett, K. S., Werner, A. P., Connell, S. O., Gagné, M., Lai, L., Moliva, J. I., Flynn, B. J., Choi, A., Koch, M. J., Foulds, K. E., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.05.21.445189 · Cited by 11
Neutralizing Antibodies Against SARS-CoV-2 Variants Induced by Natural Infection or Vaccination: A Systematic Review and Individual Data Meta-AnalysisPreprint
Chen, X., Chen, Z., Azman, A. S., Sun, R., Lu, W., Zheng, N., Zhou, J., Wu, Q., Deng, X., Zhao, Z., et al. (2021) · SSRN Electronic Journal · doi:10.2139/ssrn.3858816 · Cited by 11

Authors: Network for Genomic Surveillance in South Africa, Cele, S., COMMIT-KZN Team, Gazy, I., Jackson, L., Hwa, S.-H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S., Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B., Gosnell, B. I., Hanekom, W., Moosa, M.-Y. S., Lessells, R. J., de Oliveira, T., & Sigal, A.
Affiliations: Africa Health Research Institute (ZA)
Hebrew University of Jerusalem (IL)
Centre for the AIDS Programme of Research in South Africa (ZA)
University of KwaZulu-Natal (ZA)
Ragon Institute of MGH, MIT and Harvard (US)
Max Planck Institute for Infection Biology (DE)
Corresponding author: Sigal, Alex
ORCID: Cele, Sandile
Gazy, Inbal
Jackson, Laurelle
Hwa, Shi-Hsia
Tegally, Houriiyah
Lustig, Gila
Giandhari, Jennifer
Pillay, Sureshnee
Wilkinson, Eduan
Naidoo, Yeshnee
Karim, Farina
Ganga, Yashica
Khan, Khadija
Bernstein, Mallory
Balazs, Alejandro B.
Gosnell, Bernadett I.
Hanekom, Willem
Moosa, Mahomed-Yunus S.
Lessells, Richard J.
de Oliveira, Tulio
Sigal, Alex
Venue: Nature
Publisher: Springer Science and Business Media LLC
Published: 2021-03-29
Volume: 593
Issue: 7857
Pages: 142-146
ISSN: 0028-0836 (ISSN-L)
1476-4687
DOI: 10.1038/s41586-021-03471-w
PMC: PMC9867906
OpenAlex: W3148277587
Cited by: 651
References: 31
Citations by year: 2026: 13 · 2025: 22 · 2024: 28 · 2023: 63 · 2022: 199 · 2021: 320
FWCI: 48.26
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.springer.com/tdm (tdm)
www.springer.com/tdm (vor)
Locations: Nature (publishedVersion)
medRxiv (acceptedVersion, cc-by-nd)
PubMed (publishedVersion)
Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, other-oa)
PubMed Central (acceptedVersion)
RePEc: Research Papers in Economics (submittedVersion)
UCL Discovery (University College London) (submittedVersion)
Griffith Research Online (submittedVersion, other-oa)
Funders: South African Medical Research Council
Inyuvesi Yakwazulu-Natali
National Health Laboratory Service
Medical Research Council
National Institute on Drug Abuse (DP2DA040254)
Topics: Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
Life Sciences › Agricultural and Biological Sciences › Animal Science and Zoology › Animal Virus Infections Studies
Keywords: SARS-CoV-2, Beta variant, convalescent plasma, neutralizing antibodies, cross-neutralization, vaccine efficacy, spike protein, receptor binding domain, COVID-19 pandemic, South Africa
MeSH terms: COVID-19, SARS-CoV-2, COVID-19 Serotherapy, Animals, Antibodies, Viral, Cell Line, Chlorocebus aethiops, Humans, Immunization, Passive, Mutation, Neutralization Tests, South Africa, Time Factors, Vero Cells, Immune Evasion, Antibodies, Neutralizing

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks